Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition o...

A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer ca...

CSB Bank, JK Tyre, Pfizer, Shalby, Shoppers Stop and Ramky Infra are among companies which will announce Q4 results today.

AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger.

Here are a few stocks which may create some buzz in Friday’s trade.

With Kite, Gilead will gain cancer therapies and experimental drugs in one of the most promising fields in oncology, in addition to its hep...

The judge in the case had already decided that Merck’s patent was infringed by Gilead’s Sovaldi and Harvoni, which account for more than ha...

If expert commentaries are anything to go by, then technically, Nifty50 looks weak and it may test 7,900-7,980 in the near term.

Over the 2-year period with Subhanu Saxena at the helm, Cipla's revenues have grown by over 30% to nearly Rs 11,500 crore.

The sharp correction in the Indian markets provides a good opportunity for investors to add midcap stocks to their portfolio, say experts.

The S&P BSE Sensex lost 4.8% in March, the most since February 2013. Brokerage Sharekhan though believes that most of the issues are tempor...

Ranbaxy, founded by the family of Malvinder and Shivinder Mohan Singh, was at the centre of most of the developments for major part of the ...

Even as Hamied prepares genext leaders for Cipla, it’s humanitarian face is out to shake up industry by delivering affordable biosimilar dr...

Every country’s patent laws are need-based to that country. That’s what I am trying to fight, and nobody is listening, Hamied said.

Despite the concerns on import alerts from the USFDA and recent drug recalls, the pharma sector was one of the top performers in the last q...

On the face of it, there is nothing wrong with this kind of a deal. Pharma companies ink many such pacts on a regular basis.

Pfizer’s potential purchase of Wyeth for more than $60 billion may set off a rush to consolidate in an industry buffeted by a thinner pipel...